An observational study in SARS-CoV-2 Infection (Asymptomatic) and SARS-CoV-2 Infection (Symptomatic), sponsored by Davita Clinical Research. Completed at 11 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-03-22.
Sponsored by Davita Clinical Research · Observational
The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.
COVID-19 is a novel illness caused by the SARS-CoV-2 virus. It was declared as a global pandemic on March 11, 2020 and since that time there have been outbreaks on every continent except for Antarctica. Preliminary understanding of the virus suggests that some fraction of the population does not manifest clinical disease in response to infection, others manifest a relatively benign course of illness, and still others develop a fulminant course that eventuates in the need for intensive care, mechanical ventilation, or even death. The genetic and epigenetic basis for differential susceptibility remains unknown.
Patients receiving hemodialysis provide a good opportunity to understand genetic and epigenetic susceptibility to SARS-CoV-2. By virtue of their ongoing requirements for care, such patients cannot shelter at home or maintain social distancing, but must instead report to a clinical care setting on a thrice weekly basis. Moreover, such patients often travel to and from dialysis using shared ride services, which furthers opportunity for exposure. Preliminary estimates suggest that rates of SARS-CoV-2 positivity are 2 to 5-fold higher among hemodialysis patients than in the general public. Furthermore, frequent contact with the health care system among dialysis patients makes tracking clinical course comparatively easy.
The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 412 is above the median of 240 across 2,136 observational studies indexed under Infections.
Browse Infections studies →Davita Clinical Research is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Type A \& B participants must meet all of the following criteria:
3.2 Additional Inclusion Criteria: Type B (prior participant in genomics study)
Type B participants must meet all of the above criteria and the following criteria:
Inclusion Criteria:
Group I- Asymptomatic patients with SARS-CoV-2 Infection
Group II-Symptomatic patients with SARS-CoV-2 Infection
SARS-CoV-2 IgG
Time frame: An average of 6 months
Anti-SARS-CoV-2 IgG
Time frame: An average of 6 months
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Davita Clinical Research